Regulatory Considerations for Building an In Silico Clinical Pharmacology Backbone by 2030.

There is a widely recognized need for patients' faster access to better and safer medicines. One way to achieve that is by building and qualifying an in silico clinical pharmacology backbone. The obvious challenge is the scientific complexity of the task. What is missing is a consolidated framework to enable progress in this domain. Regulatory agencies need to take a more active role in this direction to make the clinical pharmacology backbone a reality by 2030.